🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This is an open, multi-cohort clinical study. The first phase is a dose esc...
Status
Unknown
Location
Henan Cancer Hospital
Start Date
2024-01
Trial ID
NCT06211751
Treatments Being Tested
This is a single-center, open, single-dose, self-controlled phase I clinica...
Status
Unknown
Location
The First People's Hospital of Changzhou
Start Date
2023-12
Trial ID
NCT06165822
Treatments Being Tested
This is an open, multi-center clinical study designed to evaluate the safet...
Status
Recruiting
Location
The First Affiliated Hospital of Bengbu Medical University
Start Date
2024-04-17
Trial ID
NCT07011186
Treatments Being Tested
TQB3909 is an inhibitor targeting at B-cell lymphoma (BCL)-2 protein. By bi...
Status
Unknown
Location
Jiangsu Provincial People's Hospital
Start Date
2022-02-18
Trial ID
NCT04975204
Treatments Being Tested
This is a study to assess the safety of TQB3909 monotherapy in participants...
Status
Terminated
Location
Peking University Third Hospital
Start Date
2023-10-05
Trial ID
NCT06106841
Treatments Being Tested
This is an open, single-arm, multi-center clinical study designed to evalua...
Status
Terminated
Location
The Second People's Hospital of Hefei
Start Date
2024-05-13
Trial ID
NCT06245941
Treatments Being Tested
To Evaluate the Efficacy and Safety of TQB3909 Tablets versus Investigator'...
Status
Not Yet Recruiting
Location
Henan Province
Start Date
2026-08
Trial ID
NCT07753369
Treatments Being Tested
This is a phase Ib/II clinical trial to evaluate the safety and efficacy of...
Status
Unknown
Location
Anqing Municipal Hospital
Start Date
2023-10-11
Trial ID
NCT05959694
Treatments Being Tested
TQB3909 is an inhibitor targeting B-cell lymphoma (BCL)-2 protein. By bindi...
Status
Unknown
Location
Hunan Cancer Hospital
Start Date
2023-03-02
Trial ID
NCT05775575
Treatments Being Tested